Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 12/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932138 | 0.94 | SMO (0.54) | SMOCCNT1MEN1KMT2APDE10A | |
| SCHEMBL9968379 | 0.91 | SMO (0.40) | SMOMEN1KMT2A | |
| SCHEMBL9933103 | 0.90 | ACVR1 (0.43) | SMOMEN1KMT2A | |
| SCHEMBL9931559 | 0.88 | SMO (0.47) | SMOCCNT1MEN1KMT2APDE10A | |
| SCHEMBL9932181 | 0.88 | SMO (0.47) | SMOCCNT1MEN1KMT2APDE10A | |
| SCHEMBL9932551 | 0.86 | SMO (0.41) | SMOOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL9968324 | 0.85 | MEN1 (0.44) | SMOMEN1KMT2A | |
| SCHEMBL9931667 | 0.85 | SMO (0.40) | SMOOPRM1MEN1KMT2A | |
| SCHEMBL9932736 | 0.84 | SMO (0.45) | SMOCCNT1MEN1KMT2APDE10A | |
| SCHEMBL12841515 | 0.84 | MKNK1 (0.46) | SMOCCNT1MEN1KMT2APTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885OPRM1 4174/4885OPRD1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.